ADC Target Nanobody Discovery: Target and Antigen Considerations
Successful ADC target nanobody discovery begins with selecting an appropriate target and establishing a suitable antigen presentation strategy. Since ADC targeting molecules are intended to recognize cell-surface antigens and support intracellular payload delivery, target accessibility, expression patterns, epitope characteristics, and internalization behavior should be considered during project design.
Cell-Surface Target Accessibility
ADC-targeting nanobodies need to recognize accessible epitopes on the surface of target cells. Target expression levels, membrane localization, extracellular domain structure, and expression differences between tumor and normal tissues can all influence candidate selection. Evaluating these characteristics helps define the screening strategy and the desired binding profile.
Antigen Presentation Formats
Different antigen formats can be used depending on target characteristics and the intended discovery workflow. The selection should consider whether the antigen preserves the relevant native conformation and whether it is suitable for downstream cell-based binding and internalization evaluation.
| Antigen Format |
Key Characteristics |
Potential Application |
| Recombinant Target Proteins |
Purified target proteins or extracellular domains with defined molecular characteristics. |
Initial target-binding screening and antigen-specific binder identification. |
| Target-Expressing Cell Lines |
Present target proteins in a cellular membrane environment. |
Cell-surface recognition, target specificity, and cell-based screening. |
| Whole-Cell Antigens |
Provide a broader cellular antigen presentation context. |
Discovery against native cell-associated target structures. |
| VLPs and Membrane Mimetic Systems |
Support the presentation of selected membrane-associated target structures. |
Projects involving conformationally sensitive membrane proteins. |
For challenging membrane protein targets, an appropriate antigen preparation strategy is particularly important. Explore our Nanobody Discovery for Membrane Protein Targets service for additional information about native-conformation immunization and membrane protein screening approaches.
When antigen preparation is required before the discovery project, our Immunogen Design & Production service can support suitable antigen preparation strategies. For immunization-based projects, learn more about our Camelid Animal Immunization service.
Information Required for an ADC Target Nanobody Discovery Project
Providing relevant target and project information at the beginning helps determine a suitable nanobody discovery strategy. It also allows the technical team to evaluate antigen compatibility, screening requirements, and downstream validation needs before the project starts.
| Project Information |
Details to Provide |
Purpose |
| Target Information |
Target protein name, sequence, UniProt ID, and available structural information. |
Identifies the target and supports initial feasibility assessment. |
| Target Species |
Human, cynomolgus monkey, mouse, or other relevant species. |
Defines cross-species binding and screening requirements. |
| Antigen Format |
Recombinant protein, extracellular domain, target-expressing cells, or other available formats. |
Helps determine the appropriate antigen presentation strategy. |
| Target Expression |
Available expression data, target-positive cell lines, and relevant expression characteristics. |
Supports cell-based screening design and target selection. |
| Control Materials |
Target-negative cells, related proteins, reference antibodies, or competing ligands, if available. |
Supports specificity assessment and screening controls. |
| Desired Binder Properties |
Binding affinity, cell-surface recognition, specificity, internalization, and cross-reactivity requirements. |
Defines the desired candidate profile. |
| Downstream Requirements |
Protein expression, binding validation, affinity maturation, or humanization. |
Helps establish the scope of subsequent development work. |
Clients do not need to have every project parameter finalized before making an inquiry. If the antigen format, screening platform, or desired candidate properties are still under consideration, sharing the target name and research objectives is a useful starting point for technical discussion.
ADC Target Nanobody Discovery Case Studies
Representative target-specific nanobody discovery projects demonstrate how immunization, library construction, display screening, and candidate validation can be integrated for challenging cell-surface targets. The following examples highlight NBbiolab's experience with TROP2, HER3, and PD-L1.
TROP2 Target Nanobody Discovery
Human / Cynomolgus Cross-Reactivity Cell-Based Screening VHH Candidate Validation
This project aimed to identify nanobodies that recognize both human and cynomolgus TROP2, bind TROP2-positive tumor cells, and support the evaluation of internalization capability.
One llama was immunized with recombinant TROP2 protein over a 49-day program. The resulting immune yeast display library achieved a diversity of more than 1 × 108 and a 100% insert-positive rate. Sequential MACS enrichment and FACS sorting were used to identify target-specific candidates.
Project Results
- 180 monoclonal clones were randomly selected and sequenced.
- 20 unique TROP2-specific VHH sequences were identified.
- Two lead candidates with desirable binding and developability profiles were selected.
- BS060-18 demonstrated a reported KD of 3.91 nM against human TROP2 and 6.58 nM against cynomolgus TROP2.
Download TROP2 Case Study
HER3 Target Nanobody Discovery
HER3-Specific VHH Cell-Based Binding Internalization Assessment
The HER3 project focused on discovering nanobodies capable of binding HER3-positive tumor cells and evaluating their internalization properties. Recombinant HER3 protein was used for alpaca immunization, followed by immune library construction and target-specific screening.
The resulting immune yeast display library contained more than 1 × 108 independent clones with a 100% insert-positive rate. Sequential MACS enrichment and FACS sorting were performed to isolate human HER3-binding candidates.
Project Results
- 180 monoclonal clones were selected and sequenced.
- 17 unique VHH sequences were identified.
- 10 candidates were validated as HER3-specific binders.
- Three lead candidates with desirable binding and developability profiles were identified.
- Cell-based binding analysis and internalization assessment were included in the project report.
The internalization assessment included a pH-sensitive dye-based method and a temperature-shift assay, providing additional experimental information beyond initial antigen binding.
Download HER3 Case Study
PD-L1 Target Nanobody Discovery
Human / Cynomolgus Cross-Reactivity Target-Specific VHH Cell-Based Evaluation
This project focused on identifying PD-L1-binding nanobodies with cross-reactivity to human and cynomolgus PD-L1. The discovery objectives also included binding to PD-L1-positive tumor cells and evaluating internalization capability.
One alpaca was immunized with recombinant PD-L1 protein over 49 days. The immune VHH library achieved more than 1 × 108 independent clones with a 100% insert-positive rate. MACS enrichment and FACS sorting were used to isolate target-specific candidates.
Project Results
- 10 unique PD-L1-specific VHH sequences were identified.
- All 10 candidates were reported as PD-L1-specific binders.
- Cross-reactivity to human and cynomolgus PD-L1 was included in the screening objectives and evaluation.
- Sequence properties, cell binding, antigen binding, blocking activity, and affinity measurements were included in the characterization report.
Download PD-L1 Case Study
Note: These case studies demonstrate target-specific VHH discovery and related candidate characterization. The reported discovery and validation results should not be interpreted as evidence of completed ADC conjugation, payload delivery, or in vivo therapeutic efficacy.
Frequently Asked Questions About ADC Target Nanobody Discovery
1. What is ADC Target Nanobody Discovery?
ADC Target Nanobody Discovery is a specialized binder discovery process focused on identifying VHH candidates against selected cell-surface targets for antibody-drug conjugate research. The process can combine antigen-specific immunization, VHH library construction, display-based screening, cell-based binding evaluation, and candidate validation to identify nanobodies with relevant target recognition properties.
2. Why is internalization important in ADC target nanobody discovery?
Internalization is important because many ADC mechanisms depend on the uptake of the target-bound conjugate into cells, followed by intracellular processing and payload release. Therefore, evaluating whether a nanobody-target complex undergoes cellular internalization can help assess its suitability for further ADC development. However, internalization alone does not guarantee effective payload delivery, as intracellular trafficking and linker-payload properties also influence the final outcome.
3. Which antigen formats are suitable for ADC target nanobody screening?
Depending on target characteristics and the selected discovery strategy, suitable formats may include recombinant target proteins, extracellular domains, target-expressing cell lines, whole-cell antigens, VLPs, and membrane mimetic systems. Cell-based screening is particularly useful when recognition of native cell-surface conformations is an important project requirement.
4. Can ADC target nanobodies be evaluated for cross-species reactivity?
Yes. Cross-species binding can be included in the screening and validation strategy when relevant target proteins or suitable cell-based assay materials are available. This may be important for evaluating candidate recognition of human and non-human primate targets in preclinical research. The exact species coverage depends on the target and project design.
5. Can selected ADC-targeting nanobodies undergo further engineering?
Yes. Selected VHH candidates can be considered for downstream recombinant expression, affinity optimization, and humanization according to project requirements. Explore our Antibody Affinity Maturation Service and Nanobody Humanization Service for additional information.
6. Does ADC Target Nanobody Discovery include linker-payload conjugation and ADC production?
ADC target nanobody discovery focuses on identifying and evaluating nanobody candidates for target recognition. Candidate expression, binding validation, and selected nanobody engineering services can be discussed as downstream options. Linker-payload conjugation and final ADC production are separate development activities and are not automatically included in the nanobody discovery scope.
7. What information should I provide to start an ADC target nanobody discovery project?
Useful starting information includes the target name, target sequence or UniProt ID, available antigen format, target species, target-expressing cell lines, and desired binder properties. Information about internalization requirements, cross-species reactivity, and downstream validation needs can also help the technical team assess the project.
Yeast Display VHH Discovery Service 
Immunogen Design & Production 
Premade Library Screening 
Phage Display Nanobody Discovery Service 
Animal Immunization 
Yeast Display Peptide Library Screening 
Nanobody Discovery for ADC 
Nanobody Discovery for Membrane Targets 
Nanobody Discovery for Cell Therapy 
TCR-Mimic Nanobody Discovery 
Antibody Affinity Maturation Service 
Nanobody Humanization Service 
